Samrat Pharmachem Ltd

Samrat Pharmachem, a microcap in the pharmaceuticals sector, has recently seen a change in its evaluation, reflecting its market position and performance. Despite strong management efficiency and consistent net sales growth, the company has faced challenges, including a decline in operating profit and underperformance relative to the BSE 500 index.

Samrat Pharmachem, a microcap in the pharmaceuticals sector, has recently seen an evaluation adjustment reflecting its performance metrics and market position. The company showcases strong management efficiency with a 27.61% return on capital employed and a low debt-to-EBITDA ratio, indicating solid financial health despite a slight contraction in operating profit.

Samrat Pharmachem has recently experienced a revision in its score by MarketsMOJO, reflecting changes in its market evaluation. Despite a positive financial performance in Q2 FY24-25, the stock remains in a mildly bearish range, with technical indicators suggesting ongoing challenges. However, the company demonstrates strong management efficiency and healthy long-term growth metrics.

Samrat Pharma's financial performance for the quarter ending September 2024 has shown a positive trend, with the highest profit after tax and operating profit in the last five quarters. The company's efficiency has improved, leading to higher profits and a higher operating profit margin. However, net sales have declined, resulting in a negative near term sales trend. MarketsMOJO has given a 'Hold' call for the company's stock.

Samrat Pharmachem, a microcap pharmaceutical company, has been downgraded to a 'Hold' by MarketsMOJO due to its high management efficiency, strong ability to service debt, and healthy long-term growth. The stock has also shown positive results in the latest quarter and has a bullish trend in technical factors. However, its expensive valuation and recent decline in profits may warrant caution for investors.

Samrat Pharmachem, a microcap pharmaceutical company, has received a 'Buy' rating from MarketsMOJO due to its high return on capital employed, low debt to EBITDA ratio, and consistent growth in net sales and operating profit. However, the stock's high price to book value and recent decline in profits may pose risks for investors.

Samrat Pharmachem, a microcap pharmaceutical company, has been downgraded to a 'Hold' by MarketsMOJO on October 1st, 2024. The company has shown strong long-term growth and positive results in the last two quarters. However, with an expensive valuation and recent decline in profits, it is currently recommended to be held.

Samrat Pharmachem, a microcap pharmaceutical company, has recently reached a 52-week high of Rs. 646 in the stock market. With a 'Buy' call from MarketsMOJO and outperforming the sector by 1.48%, the company's strong financials and consistent growth indicate a positive outlook. Its stock has shown resilience and is trading above all moving averages, with a 1-year performance of 57.47% compared to Sensex's 22.98%.

Samrat Pharmachem, a microcap pharmaceutical company, has recently reached a 52-week high of Rs. 645, outperforming the sector by 6.93%. MarketsMOJO has given a 'Buy' call for the stock, indicating its potential for growth and profitability. The stock has also shown strong momentum and is currently trading above its moving averages, making it a promising investment opportunity in the pharmaceutical industry.

Samrat Pharmachem, a microcap pharmaceutical company, has been making headlines with its recent stock performance. On September 13, 2024, the company's stock price reached a 52-week high of Rs. 531, outperforming the sector by 5.44%. With a 'Strong Buy' rating from MarketsMOJO and a 23.72% increase in returns in the past four days, Samrat Pharmachem is showing strong momentum and a bullish trend in the market. Its impressive 34.29% increase in the past year solidifies its position as a promising investment opportunity in the pharmaceutical industry.

Samrat Pharmachem, a microcap pharmaceutical company, has seen a significant increase in its stock price, reaching a 52-week high of Rs. 503 on September 12, 2024. The company has also received a Strong Buy rating from MarketsMOJO and has outperformed the sector by 2.21%. With a strong upward trend and positive sentiment in the market, Samrat Pharma has shown promising growth potential and has outperformed the Sensex in the past year. Its focus on the growing pharmaceutical industry and strong fundamentals make it a promising investment opportunity.

Samrat Pharmachem, a microcap pharmaceutical company, has recently reached a 52-week high of Rs. 490, outperforming the sector by 5.64%. MarketsMOJO has given a 'Buy' call for the stock, indicating its potential for growth and profitability. The stock is currently trading above its moving averages and has shown a 1-year performance of 18.24%.

Samrat Pharmachem, a microcap pharmaceutical company, has received a 'Buy' rating from MarketsMOJO due to its efficient management, low debt to EBITDA ratio, and consistent growth in net sales and operating profit. The stock is currently in a mildly bullish range and is considered attractive in terms of valuation. However, it has underperformed the market in the last year and has majority shareholders who may limit the influence of other shareholders.

Samrat Pharmachem, a microcap pharmaceutical company, has been downgraded to a 'Hold' by MarketsMOJO due to its high management efficiency, strong ability to service debt, and healthy long-term growth. In the latest quarter, the company showed positive results with a growth in Operating Profit of 92.12%. However, its profits have fallen in the past year and the stock is currently trading at a discount compared to its historical valuations. Majority shareholders are promoters and the stock is currently in a mildly bearish range. Investors are advised to hold onto their stocks and monitor the company's performance in the upcoming quarters.

Samrat Pharmachem, a leading pharmaceutical company in the microcap industry, has seen a surge in its stock price, reaching a 52-week high of Rs. 478 on August 26, 2024. Rated as a 'Buy' by MarketsMOJO, the stock has outperformed the sector by 1.58% and has been on a consecutive gain for 8 days with a 24.14% increase in returns. The stock is trading higher than its moving averages and has shown a 1-year performance of 13.96%, indicating potential for further growth.

Samrat Pharmachem, a microcap pharmaceutical company, has received a 'Buy' rating from MarketsMOJO due to its high return on capital employed (ROCE) of 26.80% and low debt to EBITDA ratio of 0.67 times. The company has shown consistent growth in net sales and operating profit, with positive results in the last two quarters. Technical indicators also suggest a bullish trend for the stock. While it is trading at a discount compared to historical valuations, its profits have fallen in the past year. Majority shareholders are promoters, but there are some risks associated with the stock. Overall, Samrat Pharmachem presents a promising investment opportunity in the pharmaceutical industry.

Samrat Pharmachem, a microcap pharmaceutical company, has seen a significant increase in its stock price, hitting a 52-week high on August 23, 2024. The stock is currently trading at Rs. 477.3, outperforming the sector by 11.42%. With a 'Hold' call from MarketsMOJO, the stock has been gaining for the past 7 days and is currently trading above its moving averages, indicating a positive trend. Investors can monitor the company's performance before making any investment decisions.

Samrat Pharmachem, a microcap pharmaceutical company, has reported a strong financial performance in the quarter ending March 2024. With a score of 21, compared to 10 in the previous quarter, the company's PBT has increased by 682.5%. Net sales have also shown a 29.09% increase year on year, and the company's operating profit margin has reached its highest in the last five quarters.

Samrat Pharmachem, a microcap pharmaceutical company, has been downgraded to 'Sell' by MarketsMOJO due to technical factors and poor long-term performance. Despite positive management efficiency and debt servicing, the company's net sales and operating profit have not shown significant growth. The stock is currently trading at a discount and has attractive valuations, but profits have fallen and majority shareholders are the promoters themselves. Investors should carefully consider these factors before making any investment decisions.